ReviewBJUI compass2025
Focal therapy in prostate cancer: Development, application and outcomes in the United Kingdom.
Review in BJUI compass, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Focal therapy in prostate cancer: Development, application and outcomes in the United Kingdom.BJUI compass · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer is a significant health issue in the United Kingdom, with rising incidence rates prompting the exploration of innovative treatment options. Focal therapy has emerged as a targeted approach that aims to treat localised prostate cancer while minimising damage to surrounding healthy tissue and subsequent adverse side effects. Focal therapy is National Institute for Health and Care Excellence (NICE)-approved treatment modality for patients with intermediate-risk localised prostate cancer. This is an evolving field, reflecting the rapidly improved understanding of both the trajectory patients face following a diagnosis of prostate cancer, and how best to apply ablative techniques. In this narrative review, we evaluate the historical development, current practices, clinical outcome reported in UK-based studies, and future directions of focal therapy for prostate cancer in the United Kingdom, highlighting its evolution as a viable treatment option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.